Fact CheckerSign in

NCT06087458Active, not recruitingPhase 1/2

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Phase 1/2a Study of VOY-101 in Subjects With Advanced Non-Neovascular Age-Related Macular Degeneration (JOURNEY)

Source: ClinicalTrials.gov · Last updated 17 Aug 2026

Brief summary (registry, in English)

The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.

Status (registry)
Active, not recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
60 (estimated)
First submitted
12 Oct 2023
Start date
21 Jun 2023
Primary completion date
Oct 2027
Lead sponsor
Perceive Biotherapeutics, Inc.
NCT number
NCT06087458

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 60
  • From 21 Jun 2023 to the primary completion date, Oct 2027
  • 16 sites in 3 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
  • Additional Systemic, Ocular, and Genetic Exclusion Criteria.

Who the study is looking for

  • Are ≥60 years of age at the time of consent.
  • Are willing and able to understand and provide written informed consent.
  • Are willing and able to return for scheduled treatment and follow-up examinations.
  • Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
  • Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
  • Absence of signs of non-exudative MNV.
  • Additional Ocular Inclusion Criteria for both eyes.
  • Meet certain genotype criteria for risk of AMD.

Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (16)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Cerulea Clinical Trials
Coordinator of this site? Confirm its status
East MelbourneAustraliaUnknown status
Sydney Retina Clinic and Day Surgery
Coordinator of this site? Confirm its status
SydneyAustraliaUnknown status
Rambam Medical Center
Coordinator of this site? Confirm its status
HaifaIsraelUnknown status
Tel-Aviv Sourasky Medical Center, Ophthalmology Division
Coordinator of this site? Confirm its status
Tel AvivIsraelUnknown status
Austin Research Center for Retina
Coordinator of this site? Confirm its status
AustinUnited StatesUnknown status
Ophthalmic Consultants of Boston
Coordinator of this site? Confirm its status
BostonUnited StatesUnknown status
Mid Atlantic Retina
Coordinator of this site? Confirm its status
Cherry HillUnited StatesUnknown status
Star Retina
Coordinator of this site? Confirm its status
Fort WorthUnited StatesUnknown status
Retina Northwest
Coordinator of this site? Confirm its status
PortlandUnited StatesUnknown status
Retina Consultants San Diego
Coordinator of this site? Confirm its status
PowayUnited StatesUnknown status
Black Hills Regional Eye Institute
Coordinator of this site? Confirm its status
Rapid CityUnited StatesUnknown status
Retinal Consultants Medical Group
Coordinator of this site? Confirm its status
SacramentoUnited StatesUnknown status
University of Utah John A. Moran Eye Center
Coordinator of this site? Confirm its status
Salt Lake CityUnited StatesUnknown status
Retina Macula Institute of AZ
Coordinator of this site? Confirm its status
ScottsdaleUnited StatesUnknown status
Retina Center of Texas
Coordinator of this site? Confirm its status
SouthlakeUnited StatesUnknown status
The Retina Institute
Coordinator of this site? Confirm its status
St LouisUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.